Table 3.
Comparison of clinical features of older patients with Parkinson's disease in different drug dose groups.
| 125 mg Levodopa/benserazide (n = 28) | 250 mg Levodopa/benserazide (n = 31) | 375 mg Levodopa/benserazide (n = 24) | F | P | 125 mg Levodopa/benserazide (n = 28) | 250 mg Levodopa/benserazide (n = 31) | 375 mg Levodopa/benserazide (n = 24) | H | P | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 66.37 ± 2.10 | 67.97 ± 2.72 | 66.95 ± 2.95 | 0.688 | 0.507 | Self-improvement Rate(%) | 35.50 ± 13.93 | 33.23 ± 7.51 | 33.40 ± 5.99 | 0.255 | 0.776 |
| Disease duration (years) | 2.80 ± 2.48 | 3.75 ± 3.55 | 5.07 ± 3.65 | 3.324 | 0.043 | UPDRS-III score (off state) | 24.75 ± 7.34 | 31.03 ± 9.11 | 36.85 ± 14.09 | 3.872 | 0.027 |
| Hoehn-Yahr stage | 1.88 ± 0.64 | 2.19 ± 0.88 | 2.25 ± 0.62 | 0.704 | 0.499 | UPDRS-III score (on state) | 14.53 ± 3.623 | 16.33 ± 9.25 | 16.96 ± 4.88 | 0.039 | 9.981 |
| BMI (kg/m2) | 23.12 ± 3.13 | 22.98 ± 3.37 | 22.12 ± 2.37 | 2.513 | 2.285 | LEDD (mg) | 150 (62.5187.5) | 300 (300,399) | 600 (566,675) | 7.677 | 0.000 |
Continuous variables with normal distribution were described as means ± standard deviations and compared using one-way ANOVA. Continuous variables with skewed distribution were described as median with interquartile range and the comparison was analyzed using the Kruskal–Wallis test. P-values with statistical significance (<0.05) are in bold.
BMI, body mass index; UPDRS-III, unified Parkinson's disease rating scale part III; LEDD, levodopa equivalent daily dosage.